Hematological Toxicity and Bone Marrow Dose-Volume Effects in Chemotherapy-Naïve Patients Treated With Whole Pelvic and Para-aortic Lymph Node Radiation Therapy For Pathologic Pelvic Lymph Node-Positive Prostate Cancer.

Authors

Julie den Hartog, Gert De Meerleer, Annouschka Laenen, Robin De Roover, Steven Joniau, Koen Slabbaert, Ann Janssens, Herlinde Dumez, Alexander Giesen, Kato Rans

Published in

Advances in radiation oncology. Volume 11. Issue 10. Pages 102072. Epub May 28, 2026.

Abstract

Whole pelvic radiation therapy combined with androgen-deprivation therapy improves prostate cancer-specific survival in pathologic pelvic lymph node-positive prostate cancer. Elective para-aortic radiation therapy may further improve clinical outcomes and is under investigation in the Para-Aortic Radiotherapy (PART) study (NCT03079323). This study investigated the effect of whole pelvic radiation therapy plus PART on hematological toxicity (HemT).
HemT and bone marrow (BM) dose-volume relationships were analyzed in the first 75 PART patients enrolled in the University Hospitals Leuven, all receiving 24 months of androgen-deprivation therapy or antiandrogen therapy. Hematological changes were assessed longitudinally. Associations were analyzed using linear models for repeated measures, with false discovery rate correction.
At 57-months median follow-up (median age, 66 years), no HemT caused treatment interruption. All blood parameters declined significantly after radiation therapy (all P < .01 at 1, 3, 6, and 24 months). Grade 4 toxicity was limited to lymphopenia (acute 7%, late 1%), grade 3 leukopenia occurred in 1% acutely and late. No grade 3-4 anemia or grade 2-4 thrombocytopenia was seen. BM dosimetric analysis showed that larger low-dose volumes (V3, V5, and V10) in the lower pelvis, whole pelvis, and whole pelvis plus retroperitoneal region were significant associated with greater late absolute lymphocyte count (ALC) decline. Every 100 cm³ increase in absolute volume correlated with a late ALC decrease of -0.04 to -0.08 × 10⁹ /L (all false discovery rates; P ≤ .01).
Extended-field radiation therapy is clinically well tolerated in chemotherapy-naïve pathologic pelvic lymph node-positive prostate cancer patients, with no toxicity-related treatment interruptions. However, persistent lymphopenia was observed. Dose-dependent association between low-dose BM irradiation (V3-V10) and late ALC decline supports further research into BM-sparing techniques to reduce long-term toxicity.

PMID:
42519375
Bibliographic data and abstract were imported from PubMed on 29 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.